Harvard Apparatus Regenerative Technology Inc. (HRGN)
OTCMKTS · Delayed Price · Currency is USD
1.677
-0.003 (-0.15%)
At close: Mar 19, 2026
HRGN Revenue
In the year 2025, Harvard Apparatus Regenerative Technology had annual revenue of $704.00K with 63.72% growth. Harvard Apparatus Regenerative Technology had revenue of $219.00K in the quarter ending December 31, 2025, a decrease of -15.12%.
Revenue
704.00K
Revenue Growth
+63.72%
P/S Ratio
41.89
Revenue / Employee
88.00K
Employees
8
Market Cap
29.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 704.00K | 274.00K | 63.72% |
| Dec 31, 2024 | 430.00K | 327.00K | 317.48% |
| Dec 31, 2023 | 103.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zeo ScientifiX | 5.56M |
| Zenith Capital | 500.00K |
| Provectus Biopharmaceuticals | 350.44K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 115.29K |
Harvard Apparatus Regenerative Technology News
- 2 months ago - Harvard Apparatus Regenerative Technology Collaborates with University of Southern California to Test Treatment for Esophageal Disease - GlobeNewsWire
- 1 year ago - Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children's Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia - GlobeNewsWire
- 1 year ago - Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors - GlobeNewsWire
- 1 year ago - Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial - GlobeNewsWire
- 2 years ago - Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 years ago - Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 years ago - Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy - GlobeNewsWire
- 2 years ago - Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus - GlobeNewsWire